Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA, a Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of clopidogrel and 300 mg loading aspirin administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 200 mg cilostazol and 300 mg loading aspirin were assessed through NIHSS, mRS, and possible adverse effects

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• the investigators included both genders with eligible ages ranging between 18-75 years, with the first-ever presentation with large-vessel minor ischemic stroke or TIA who received antiplatelet treatment within the first 24 hours of the onset of ischemic stroke. Patients are not eligible for rt-PA treatment

Locations
Other Locations
Egypt
Kafr Elsheikh University Hospital
RECRUITING
Kafr Ash Shaykh
Contact Information
Primary
mohamed G. Zeinhom, MD
mohamed_gomaa@med.kfs.edu.eg
2001009606828
Backup
sherihan R. ahmed, MD
sherihan_rezq@med.kfs.edu.eg
2001113432342
Time Frame
Start Date: 2022-05-01
Estimated Completion Date: 2024-10-10
Participants
Target number of participants: 870
Treatments
Active_comparator: cilostazol and aspirin
The cilostazol arm will receive (a 200 mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Active_comparator: clopidogrel and aspirin
The clopidogrel arm will receive (a 300 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 75 mg once daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Related Therapeutic Areas
Sponsors
Leads: Kafrelsheikh University

This content was sourced from clinicaltrials.gov